Highly active antiretroviral therapy (HAART) has significantly reduced the number of deaths caused by AIDS. However, the antiviral efficacy of HAART comprising protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) is frequently accompanied by a decrease in patients' quality of life. PI-based therapies often fail due to poor adherence caused by heavy pill burden, complex dosing schedules and undesirable side effects. The current trend is to switch from PI-based to PI-sparing regimens consisting of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and NRTIs. Despite some encouraging results from NNRTI-containing therapies, two major concerns in using the currently available NNRTIs remain: 1) low genetic barrier to the emergence of resistance and 2) cross-resistance due to single mutations that often render the whole class of NNRTIs ineffective. Clearly, new and improved NNRTIs are needed to address these concerns.
AlbrightAVErickson-ViitanenSO'ConnorMFrankIRaynerMM & Gonzalez-ScaranoF (2000) Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro. AIDS Research & Human Retroviruses16: 1527–1537.
2.
BabaMShigetaSYuasaSTakashimaHSekiyaKUbasawaMTanakaHMiyasakaTWalkerRT & De ClercqE (1994) Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrobial Agents & Chemotherapy38: 688–692.
3.
BabaMYuasaSNiwaTYamamotoMYabuuchiSTakashimaHUbasawaMTanakaHMiyasakaTWalkerRTBalzariniJDe ClercqE & ShigetaS (1993) Effect of human serum on the in vitro anti-HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) derivatives as related to their lipophilicity and serum protein binding. Biochemical Pharmacology45: 2507–2512.
4.
BachelerLJeffreySHannaGD'AquilaRWallaceLLogueKCordovaBHertogsKLarderBBuckeryRBakerDGallagherKScarnatiHTritchR & RizzoC (2001) Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. Journal of Virology75: 4999–5008.
5.
BachelerLTAntonEDKudishPBakerDBunvilleJKrakowskiKBollingLAujayMWangXVEllisDBeckerMFLasutALGeorgeHJSpaldingDRHollisG & AbremskiK (2000) Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrobial Agents & Chemotherapy44: 2475–2484.
6.
BarnardJBorkowG & ParniakMA (1997) The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry36: 7786–7792.
7.
BarreiroPSorianoVBlancoFCasimiroCde la CruzJJ & Gonzalez-LahozJ (2000) Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS14: 807–812.
8.
BellCMatthewsGV & NelsonMR (2003) Non-nucleoside reverse transcriptase inhibitors-an overview. International Journal of STD & AIDS14: 71–77.
9.
BHIVA (2003) BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine4 (Suppl 1): 1–41. http://www.bhiva.org/guidelines/2003/hiv/index.html
10.
BorkowGBarnardJNguyenTMBelmonteAWainbergMA & ParniakMA (1997) Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. Journal of Virology71: 3023–3030.
11.
BuckheitRW (2001) Non-nucleoside reverse transcriptase inhibitors: Perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection. Expert Opinion on Investigational Drugs10: 1423–1442.
12.
BuckheitRWJr.KinjerskiTLFliakas-BoltzVRussellJDStupTLPallanschLABrouwerWGDaoDCHarrisonWA & SchultzRJ (1995) Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide. Antimicrobial Agents & Chemotherapy39: 2718–2727.
13.
BuckheitRWJr.WatsonKFliakas-BoltzVRussellJLoftusTLOsterlingMCTurpinJAPallanschLAWhiteELLeeJWLeeSHOhJWKwonHSChungSG & ChoEH (2001) SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrobial Agents & Chemotherapy45: 393–400.
14.
BuckheitRWJrWhiteELFliakas-BoltzVRussellJStupTLKinjerskiTLOsterlingMCWeigandA & BaderJP (1999) Unique anti-human immunodeficiency virus activities of the non-nucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrobial Agents & Chemotherapy43: 1827–1834.
15.
CampianiGRamunnoAMagaGNacciVFattorussoCCatalanottiBMorelliE & NovellinoE (2002) Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present and future perspectives. Current Pharmaceutical Design8: 615–657.
16.
ConwayB (2000) Initial therapy with protease inhibitor-sparing regimens: Evaluation of nevirapine and delavirdine. Clinical Infectious Diseases30 (Suppl 2): S130–S134.
17.
CorbettJWKoSSRodgersJDGearhartLAMagnusNABachelerLTDiamondSJeffreySKlabeRMCordovaBCGarberSLogueKTrainorGLAndersonPS & Erickson-ViitanenSK (2000) Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. Journal of Medicinal Chemistry43: 2019–2030.
18.
CorbettJWKoSSRodgersJDJeffreySBachelerLTKlabeRMDiamondSLaiCMRabelSRSayeJAAdamsSPTrainorGLAndersonPS & Erickson-ViitanenSK (1999) Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy43: 2893–2897.
19.
Cozzi-LepriAPhillipsANd'ArminioMonforte APiersantelliNOraniAPetrosilloNLeonciniFScerboATundoPAbresciaN & MoroniM (2002) Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. Journal of Infectious Diseases185: 1062–1069.
20.
CreaghTRuckleJLTolbertDTGiltnerJEiznhamerDADuttaBFlavinMT & XuZQ (2001) Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrobial Agents & Chemotherapy45: 1379–1386.
21.
DaveyRTJr.ChaittDGReedGFFreimuthWWHerpinBRMetcalfJAEastmanPSFalloonJKovacsJAPolisMAWalkerREMasurHBoyleJColemanSCoxSRWathenLDaenzerCL & LaneHC (1996) Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrobial Agents & Chemotherapy40: 1657–1664.
22.
De ClercqE (1999) Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco54: 26–45.
23.
DeeksSG (2001) International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. Journal of Acquired Immune Deficiency Syndrome26 (Suppl 1): S25–33.
24.
DemeterLMShaferRWMeehanPMHolden-WiltseJFischlMAFreimuthWWParaMF & ReichmanRC (2000) Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrobial Agents & Chemotherapy44: 794–797.
25.
DHHS Panel on Clinical Practices for Treatment of HIV Infection (2003) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescentshttp://www.aidsinfo.nih.gov/guidelines/adult/html
26.
DingJDasKMoereelsHKoymansLAndriesKJanssenPAHughesSH & ArnoldE (1995) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nature Structural Biology2: 407–415.
27.
EiznhamerDACreaghTRuckleJLTolbertDTGiltnerJDuttaBFlavinMTJentaT & XuZQ (2002) Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. HIV Clinical Trials3: 435–450.
28.
EricksonDAMatherGTragerWFLevyRH & KeirnsJJ (1999) Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metabolism & Disposition27: 1488–1495.
29.
EstradaVDe VillarNGLarradMTLopezAGFernandezC & Serrano-RiosM (2002) Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clinical Infectious Diseases35: 69–76.
30.
FlavinMTRizzoJDKhilevichAKucherenkoASheinkmanAKVilaychackVLinLChenWGreenwoodEMPengsuparpTPezzutoJMHughesSHFlavinTMCibulskiMBoulangerWAShoneRL & XuZQ (1996) Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers. Journal of Medicinal Chemistry39: 1303–1313.
31.
FletcherRSSyedKMithaniSDmitrienkoGI & ParniakMA (1995) Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme. Biochemistry34: 4346–4353.
32.
FriedlandGHPollardRGriffithBHughesMMorseGBassettRFreimuthWDemeterLConnickENevinTHirschM & FischlM (1999) Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. Journal of Acquired Immune Deficiency Syndrome21: 281–292.
33.
FujiwaraTSatoAEl-FarrashMMikiSAbeKIsakaYKodamaMWuYChenLBHaradaHSugimotoHHatanakaM & HinumaY (1998) S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy42: 1340–1345.
34.
GazzardBGPozniakALRosenbaumWYeniGPStaszewskiSArastehKDe DierKPeetersMWoodfallBStebbingJ & Vant' KloosterGA (2003) An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS17: F49–F54.
35.
GruzdevBRakhmanovaADoubovskayaEYakovlevAPeetersMRinehartADe DierKDijkPBParysW & Van't KloosterG (2003) A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS17: 2487–2894.
36.
GuayLAMusokePFlemingTBagendaDAllenMNakabiitoCShermanJBakakiPDucarCDeseyveMEmelLMirochnickMFowlerMGMofensonLMiottiPDransfieldKBrayDMmiroF & JacksonJB (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet354: 795–802.
37.
HarrisM (2003) Efficacy and durability of nevirapine in antiretroviral-experienced patients. Journal of Acquired Immune Deficiency Syndrome34 (Suppl 1): S53–S58.
38.
HarrisM & MontanerJS (2000) Clinical uses of non-nucleoside reverse transcriptase inhibitors. Reviews in Medical Virology10: 217–229.
39.
HavlirDCheesemanSHMcLaughlinMMurphyREriceASpectorSAGreenoughTCSullivanJLHallD & MyersM (1995a) High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. Journal of Infectious Diseases171: 537–545.
40.
HavlirDMcLaughlinMM & RichmanDD (1995b) A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of >500/mm3: AIDS Clinical Trials Group Protocol 208. Journal of Infectious Diseases172: 1379–1383.
41.
HolmbergSDMoormanACWilliamsonJMTongTCWardDJWoodKCGreenbergAE & JanssenRS (2002) Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet360: 1747–1748.
42.
HopkinsALRenJTanakaHBabaMOkamatoMStuartDI, & StammersDK (1999) Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. Journal of Medicinal Chemistry42: 4500–4505.
43.
HsiouYDasKDingJClarkADJr.KleimJPRosnerMWinklerIRiessGHughesSH & ArnoldE (1998) Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance. Journal of Molecular Biology284: 313–323.
44.
HsiouYDingJDasKClarkADJr.BoyerPLLewiPJanssenPAKleimJPRosnerMHughesSH & ArnoldE (2001) The Lys103Asn mutation of HIV-1 RT: A novel mechanism of drug resistance. Journal of Molecular Biology309: 437–445.
45.
KashmanYGustafsonKRFullerRWCardellinaJH2ndMcMahonJBCurrensMJBuckheitRWJrHughesSHCraggGM & BoydMR (1992) The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. Journal of Medicinal Chemistry35: 2735–2743.
46.
KohlstaedtLAWangJFriedmanJMRicePA & SteitzTA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science256: 1783–1790.
47.
KontorinisN & DieterichDT (2003) Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Seminars in Liver Disease23: 173–182.
48.
KoupRAMerluzziVJHargraveKDAdamsJGrozingerKEcknerRJ & SullivanJL (1991) Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodi-azepinone BI-RG-587. Journal of Infectious Diseases163: 966–970.
49.
LamsonMJSaboJPMacGregorTRPavJWRowlandLHawiACappolaM & RobinsonP (1999) Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharmaceutics & Drug Disposition20: 285–291.
50.
BrownLeigh AJFrostSDMathewsWCDawsonKHellmannNSDaarESRichmanDD & LittleSJ (2003) Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. Journal of Infectious Diseases187: 683–686.
51.
ManfrediRCalzaL & ChiodoF (2002) A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: First-line versus salvage use. Journal of Antimicrobial Chemotherapy49: 723–729.
52.
MarseilleEKahnJGMmiroFGuayLMusokePFowlerMG & JacksonJB (1999) Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet354: 803–809.
MartinezECongetILozanoLCasamitjanaR & GatellJM (1999) Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS13: 805–810.
55.
MartinezEGarcia-ViejoMABlanchL & GatellJM (2001b) Lipodystrophy syndrome in patients with HIV infection: Quality of life issues. Drug Safety24: 157–166.
56.
MatthewsGVSabinCAMandaliaSLampeFPhillipsANNelsonMRBowerMJohnsonMA & GazzardBG (2002) Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: A cohort study. AIDS16: 53–61.
57.
MerluzziVJHargraveKDLabadiaMGrozingerKSkoogMWuJCShihCKEcknerKHattoxSAdamsJRosehthalASFaanesREcknerRJKoupRA & SullivanJL (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science250: 1411–1413.
58.
MirochnickMFentonTGagnierPPavJGwynneMSiminskiSSperlingRSBeckermanKJimenezEYogevRSpectorSA & SullivanJL (1998) Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. Journal of Infectious Diseases178: 368–374.
59.
MurphyRLSommadossiJPLamsonMHallDBMyersM & DusekA (1999) Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. Journal of Infectious Diseases179: 1116–1123.
60.
NegredoECruzLParedesRRuizLFumazCRBonjochAGelSTuldraABalagueMJohnstonSArnoAJouATuralCSireraGRomeuJ & ClotetB (2002a) Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clinical Infectious Diseases34: 504–510.
61.
NegredoERibaltaJParedesRFerreRSireraGRuizLSalazarJReissPMasanaL & ClotetB (2002b) Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS16: 1383–1389.
62.
ParaMFMeehanPHolden-WiltseJFischlMMorseGShaferRDemeterLMWoodKNevinTVirani-KetterN & FreimuthWW (1999) ACTG 260: A randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Antimicrobial Agents & Chemotherapy43: 1373–1378.
PenzakSR, & ChuckSK (2000) Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment. Scandinavian Journal of Infectious Diseases32: 111–123.
65.
Perez-MolinaJA (2002) Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clinical Trials3: 279–286.
66.
Perez-MolinaJAPerezNr RMirallesPCosinJPadillaBBerenguerJ & BouzaE (2001) Nelfinavir plus nevirapine plus two NRTIS as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment. HIV Clinical Trials2: 1–5.
67.
PodzamczerDFerrerEConsiglioEGatellJMPerezPPerezJLLunaEGonzalezAPedrolELozanoLOcanaILlibreJMCasiroAArandaMBarrufetPMartinez-LacasaJMiroJMBadiaXCasadoALupoSCahnPManosM & EstelaJ (2002) A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antiviral Therapy7: 81–90.
68.
PollardRBRobinsonP & DransfieldK (1998) Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clinical Therapy20: 1071–1092.
69.
RenJMiltonJWeaverKLShortSAStuartDI & StammersDK (2000) Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure with Folding & Design8: 1089–1094.
70.
RenJNicholsCBirdLChamberlainPWeaverKShortSStuartDI & StammersDK (2001) Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. Journal of Molecular Biology312: 795–805.
71.
RichmanDDHavlirDCorbeilJLooneyDIgnacioCSpectorSASullivanJCheesemanSBarringerKPaulettiDShihC-KMyersM & GriffinJ (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology68: 1660–1666.
72.
RiskaPSJosephDPDinalloRMDavidsonWCKeirnsJJ & HattoxSE (1999) Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug Metabolism & Disposition27: 1434–1447.
73.
RobbinsGKDe GruttolaVShaferRWSmeatonLMSnyderSWPettinelliCDubeMPFischlMAPollardRBDelapenhaRGedeonLvan der HorstCMurphyRLBeckerMID'AquilaRTVellaSMeriganTC & HirschMS (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. New England Journal of Medicine349: 2293–22303.
74.
RuizLNegredoEDomingoPParedesRFranciaEBalagueMGelSBonjochAFumazCRJohnstonSRomeuJLangeJ & ClotetB (2001) Antiretroviral treatment simplification with nevi-rapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. Journal of Acquired Immune Deficiency Syndromes27: 229–236.
75.
SankatsingSUWeverlingGJPeetersMVan't KloosterGGruzdevBRakhmanovaADannerSAJurriaansSPrinsJM & LangeJM (2003) TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS17: 2623–2627.
76.
ScottLJ & PerryCM (2000) Delavirdine: A review of its use in HIV infection. Drugs60: 1411–1444.
77.
SheltonMJHewittRGAdamsJDella-ColettaACoxS & MorseGD (2003) Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. Antimicrobial Agents & Chemotherapy47: 1694–1699.
78.
StaszewskiSMorales-RamirezJTashimaKTRachlisASkiestDStanfordJStrykerRJohnsonPLabriolaDFFarinaDManionDJ & RuizNM (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New England Journal of Medicine341: 1865–1873.
79.
SullivanAKNelsonMRShawAMoyleGJMandaliaSGazzardBG & AsboeD (2000) Efficacy of a nelfinavir- and nevirapine-containing salvage regimen. HIV Clinical Trials1: 7–12.
80.
SzczechGMFurmanPPainterGRBarryDWBorroto-EsodaKGrizzleTBBlumMRSommadossiJEndohRNiwaTYamamotoM & MoxhamC (2000) Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy44: 123–130.
81.
TashimaKTCaliendoAMAhmadMGormleyJMFiskeWDBrennanJM & FlaniganTP (1999) Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. Journal of Infectious Diseases180: 862–864.
82.
TranJQPetersenCGarrettMHeeB & KerrBM (2002) Pharmacokinetic interaction between amprenavir and delavirdine: Evidence of induced clearance by amprenavir. Clinical Pharmacology & Therapeutics72: 615–626.
83.
van HeeswijkRPVeldkampAIMulderJWMeenhorstPLWitFWLangeJMDannerSAFoudraineNAKwakkelsteinMOReissPBeijnenJH & HoetelmansRM (2000) The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. DAIDS14: F77–F82.
84.
Van HerrewegeYMichielsJVan RoeyJFransenKKestensLBalzariniJLewiPVanhamG & JanssenP (2004) In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrobial Agents & Chemotherapy48: 337–339.
85.
van LeeuwenRKatlamaCMurphyRLSquiresKGatellJHorbanAClotetBStaszewskiSvan EedenAClumeckNMoroniMPaviaATSchmidtREGonzalez-LahozJMontanerJAntunesFGulickRBanhegyiDvan der ValkMReissPvan WeertLvan LethFJohnsonVASommadossiJP & LangeJM (2003) A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS17: 987–999.
86.
WainbergMA (2003) HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. Journal of Acquired Immune Deficiency Syndrome34 (Suppl. 1): S2–S7.
87.
ZussmanALaraLLaraHHBentwichZ & BorkowG (2003) Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS17: 653–661.
